RxDoctor Payments Data

Roland Sabundayo, MD

Internal Medicine · Baltimore, MDNPI 1760429187

Payments from drug & device makers

$2,169in general payments, 2019–2025

Across 129 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$370
  • Novo Nordisk$326
  • Pfizer$208
  • Sanofi-aventis U.S. LLC$171
  • Merck$146
  • Amgen$136
  • plus $811 from 15 others

What the payments were for

  • Food & beverage$2,15099%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,169 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$133,833
Medicare patients
288
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$77,054
OzempicSemaglutide39$63,029
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,007
JanuviaSitagliptin Phosphate32$46,150
JardianceEmpagliflozin22$23,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$20,761
XareltoRivaroxaban13$16,809
Tresiba Flextouch U-100Insulin Degludec31$14,512
Breo ElliptaFluticasone/Vilanterol13$11,492
MounjaroTirzepatide11$11,313
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,367
Combivent RespimatIpratropium/Albuterol Sulfate11$5,416
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,269
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,172
Incruse ElliptaUmeclidinium Bromide15$5,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$208$77,05492 claims
Novo NordiskOzempic$326$63,02939 claims
GileadGenvoya$65$47,00712 claims
MerckJanuvia$146$46,15032 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$93$37,31462 claims
Boehringer IngelheimJardiance, Combivent Respimat$57$28,71933 claims
Lilly USA, LLCMounjaro$126$11,31311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →